Related Experiment Video
Updated: Jun 1, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Lipid abnormalities in patients with chronic kidney disease
Insights
Patients with chronic kidney disease (CKD) experience higher cardiovascular disease risks due to dyslipidemia, characterized by altered triglyceride and high-density lipoprotein (HDL) levels. Understanding these lipoprotein abnormalities is crucial for managing cardiovascular outcomes in CKD.
Area of Science:
- Nephrology
- Cardiology
- Metabolic Disorders
Background:
- Cardiovascular disease (CVD) is the primary cause of death in chronic kidney disease (CKD) patients.
- Dyslipidemia is common in CKD, typically presenting as elevated triglycerides and reduced high-density lipoproteins (HDL), rather than high cholesterol.
Purpose of the Study:
- To investigate the complex lipoprotein metabolism abnormalities in chronic kidney disease (CKD).
- To understand how these dyslipidemias contribute to the increased cardiovascular morbidity and mortality in CKD patients.
Main Methods:
- Analysis of apolipoprotein (apo) B-containing lipoproteins (apoB-48 and apoB-100) metabolism.
- Evaluation of abnormalities in apoA-containing lipoproteins.
- Assessment of enzymatic delipidation and receptor-mediated clearance pathways.
Main Results:
- Significant abnormalities in the metabolism of both gut-derived (apoB-48) and liver-derived (apoB-100) lipoproteins were observed.
- Reduced enzymatic delipidation and receptor removal led to increased concentrations of atherogenic apoB-containing remnants.
- Altered apoA-lipoproteins were linked to lower HDL levels and a pro-inflammatory state in CKD.
Conclusions:
- Dyslipidemia in CKD involves complex alterations in lipoprotein metabolism, contributing to cardiovascular risk.
- Therapeutic strategies for CKD cardiovascular outcomes must address multiple facets of lipoprotein abnormalities.
- Targeting these specific metabolic pathways may be essential for improving cardiovascular health in CKD patients.
Abstract:
Cardiovascular disease is increased in patients with chronic kidney disease (CKD) and is the principle cause of morbidity and mortality in these patients. Dyslipidemia, while common in these patients, is usually not characterized by elevated cholesterol, except in those patients with massive proteinuria. Qualitatively, increased triglycerides and reduced high-density lipoproteins (HDL) are most frequently described. Extensive abnormalities in the metabolism of apolipoprotein (apo) B-containing lipoproteins have been demonstrated, including those derived from the gut (apoB-48) as well as those derived from hepatic synthesis (apoB-100). Decreased enzymatic delipidation, in addition to reduced receptor removal of these lipoproteins, results in increased concentrations of these apoB-containing moieties, and in particular, their atherogenic remnants. Abnormalities in apoA-containing lipoproteins are also present and these changes may contribute not only to the lower levels of HDL seen, but also to the proinflammatory state that is frequently present in CKD patients. As a result, therapeutic strategies designed to modify atherosclerotic-caused outcomes in CKD may require multiple approaches.
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management
Diabetic Nephropathy
Nephrotic Syndrome I : Introduction
